Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07396337Phase 2Recruiting

Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

Role: lead

NCT06532058Phase 2Recruiting

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT06388772Phase 1Completed

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

Role: lead

NCT06380699Phase 1Completed

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Role: lead

All 4 trials loaded